John Murphy: Generics, Biosimilars, and U.S. Policy
In this episode of the Vital Health Podcast, host Duane Schulthess speaks with John Murphy, President and CEO of the Association for Accessible Medicines (AAM), to discuss how U.S. purchasing dynamics and thin margins drive shortages, the evolving biosimilar landscape amid insurer vertical integration, the Inflation Reduction Act (IRA)’s ripple effects on plan risk and rebates, Most Favored Nation (MFN) policy proposals, and what it will take to reshore capacity while preserving competition and patient access.
Key Topics:
Generic Pricing Pressures: Purchaser consolidation, sterile…
The skinny
The skinny isn't ready yet — notes appear once the transcript is processed.